Amendments to the Claims

Please cancel claims 4, 7, 8, 15, 16 and 18-20, and amend claims 1, 5, 6, 9, 10, 11, 12, 13 and 17. The Claim Listing below will replace all prior versions, and listings, of the claims in the application:

Claim Listing:

1. (currently amended) An aqueous immunogenic composition which, after administration to a subject, is able to induce an immune response that is bactericidal against serogroups B, C, W135 and Y of *N.meningitidis*, wherein the composition comprises: (i) a conjugated serogroup C capsular saccharide antigen; (ii) a conjugated serogroup W135 capsular saccharide antigen; (iii) a conjugated serogroup Y capsular saccharide antigen; and (iv) ~~one or more polypeptide antigens from serogroup B~~ a 'NadA' protein in oligomeric form, a '741' protein, a '936' protein, a '953' protein and a '287' protein,

   wherein:

   the NadA has an amino acid sequence which: (a) has 50% or more identity to SEQ ID NO:2; and/or (b) comprises a fragment of at least 7 consecutive amino acids of SEQ ID NO:1 and comprising an epitope from SEQ ID NO:1;

   the 741 has an amino acid sequence which: (a) has 50% or more identity to SEQ ID NO:3; and/or (b) comprises a fragment of at least 7 consecutive amino acids of SEQ ID NO:3 and comprising an epitope from SEQ ID NO:3;

   the 936 has an amino acid sequence which: (a) has 50% or more identity to SEQ ID NO:4; and/or (b) comprises a fragment of at least 7 consecutive amino acids of SEQ ID NO:4 and comprising an epitope from SEQ ID NO:4;

   the 953 has an amino acid sequence which: (a) has 50% or more identity to SEQ ID NO:5; and/or (b) comprises a fragment of at least 7 consecutive amino acids of SEQ ID NO:5 and comprising an epitope from SEQ ID NO:5; and

   the 287 has an amino acid sequence which: (a) has 50% or more identity to SEQ ID NO:6; and/or (b) comprises a fragment of at least 7 consecutive amino acids of SEQ ID NO:6 and comprising an epitope from SEQ ID NO:6.

2. (original) The composition of claim 1, further comprising: (v) a conjugated serogroup A capsular saccharide antigen.

3. (original) The composition of claim 2, wherein the serogroup A capsular saccharide is modified such that at least 20% of its monosaccharide units do not have –OH at either of the 3 and 4 positions.

4. (canceled)

5. (currently amended) The composition of ~~any preceding~~ claim 1, wherein the conjugated saccharides are oligosaccharides.

6. (currently amended) The composition of ~~any preceding~~ claim 1, wherein the saccharides are conjugated to a carrier protein selected from: diphtheria toxoid, tetanus toxoid, *H.influenzae* protein D, and CRM_{197}.

7. (canceled)

8. (canceled)

9. (currently amended) The composition of ~~claim 8~~ claim 1, comprising: a first polypeptide comprising amino acid sequence SEQ ID NO:2; a second polypeptide comprising amino acid sequence SEQ ID NO:7; and a third polypeptide comprising amino acid sequence SEQ ID NO:8;

10. (currently amended) The composition of ~~any preceding~~ claim 1, further comprising a saccharide antigen that protects against *H.influenzae* type B (Hib).

11. (currently amended) The composition of ~~any preceding~~ claim 1, further comprising an antigen that protects against *Streptococcus pneumoniae*.

12. (currently amended) The composition of ~~any preceding~~ claim 1 comprising an aluminium phosphate adjuvant.

13. (currently amended) The composition of ~~any preceding~~ claim 1, packaged in a hermetically-sealed container.

14. (original) The composition of claim 13, wherein the container is a vial or a syringe.

15. (canceled)

16. (canceled)

17. (currently amended) A method for raising an antibody response in a mammal, comprising administering a composition of ~~any one of claims 1 to 15~~ claim 1 to the mammal.

18. (canceled)

19. (canceled)

20. (canceled)